Functional inactivation of duodenal ferroportin by hepcidin drives iron-dependent degradation of DMT1 in lysosomes

A Angeliki Katsarou (1Lady Davis Institute for Medical Research, Montreal, Canada) A Apostolos Galaris C Carine Fillebeen (1Lady Davis Institute for Medical Research, Jewish General Hospital, Department of Medicine, McGill University, Montreal, QC, Canada) E Edouard Charlebois (1Lady Davis Institute for Medical Research, Jewish General Hospital, Department of Medicine, McGill University, Montreal, QC, Canada) A Aleksandr Rabinovich (2Ferring Research Institute Inc, San Diego, United States) K Kazimierz Wisniewski (2Ferring Research Institute Inc, San Diego, United States) J John Kraus (2Ferring Research Institute Inc, San Diego, United States) K Karine Audette (3University of Montreal, Montreal, Canada) J Jean Duchaine V Vivek Venkataramani (4Julius-Maximilians Universität Würzburg, Würzburg, Germany) B Bernhard Michalke T Tanvi Javkar (6McGill University, Montreal, Canada) A Alex Gregorieff (6McGill University, Montreal, Canada) A Anastasia Velentza (2Ferring Research Institute Inc, San Diego, United States) K Kostas Pantopoulos (1Lady Davis Institute for Medical Research, Jewish General Hospital, Department of Medicine, McGill University, Montreal, QC, Canada)

Abstract

Abstract Hepcidin regulates systemic iron homeostasis by inhibiting iron absorption and recycling through degradation of the iron exporter ferroportin in enterocytes and macrophages. While its effects on macrophages are well characterized, ferroportin regulation in duodenal enterocytes remains less understood. Several studies suggest that duodenal ferroportin is relatively resistant to hepcidin, implying tissue-specific regulatory mechanisms. To investigate this, we used wild-type and hepcidin-deficient Hjv⁻/⁻ mice, a model of hemochromatosis. Synthetic hepcidin administration significantly reduced plasma iron and ferroportin levels in the spleen and liver. In duodenal enterocytes, hepcidin decreased ferroportin and apical divalent metal transporter 1 (DMT1) in wild-type mice. In Hjv⁻/⁻ animals, where both transporters are overexpressed, hepcidin suppressed DMT1 but not ferroportin, yet duodenal iron levels increased—indicating functional ferroportin inactivation. This DMT1 suppression was reproduced in murine intestinal organoids treated with hepcidin or iron, regardless of ferroportin degradation. Short-term high-iron diet in wild-type mice or high-dose hepcidin in Hjv⁻/⁻ mice led to duodenal iron accumulation and degradation of both transporters. Notably, DMT1 (but not ferroportin) degradation was partially rescued by the lysosomal inhibitor chloroquine. These findings demonstrate that hepcidin can degrade duodenal ferroportin under physiological expression, but higher doses are needed when it is overexpressed. Even when hepcidin fails to degrade ferroportin, it can still occlude its iron export channel, leading to intracellular iron accumulation and iron-dependent lysosomal degradation of DMT1. Thus, hepcidin controls iron absorption through dual targeting of duodenal iron transporters via distinct mechanisms: direct functional inactivation of ferroportin that indirectly triggers DMT1 degradation.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 4678-4678
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (15)

A

Angeliki Katsarou

1Lady Davis Institute for Medical Research, Montreal, Canada

A

Apostolos Galaris

C

Carine Fillebeen

1Lady Davis Institute for Medical Research, Jewish General Hospital, Department of Medicine, McGill University, Montreal, QC, Canada

E

Edouard Charlebois

1Lady Davis Institute for Medical Research, Jewish General Hospital, Department of Medicine, McGill University, Montreal, QC, Canada

A

Aleksandr Rabinovich

2Ferring Research Institute Inc, San Diego, United States

K

Kazimierz Wisniewski

2Ferring Research Institute Inc, San Diego, United States

J

John Kraus

2Ferring Research Institute Inc, San Diego, United States

K

Karine Audette

3University of Montreal, Montreal, Canada

J

Jean Duchaine

V

Vivek Venkataramani

4Julius-Maximilians Universität Würzburg, Würzburg, Germany

B

Bernhard Michalke

T

Tanvi Javkar

6McGill University, Montreal, Canada

A

Alex Gregorieff

6McGill University, Montreal, Canada

A

Anastasia Velentza

2Ferring Research Institute Inc, San Diego, United States

K

Kostas Pantopoulos

1Lady Davis Institute for Medical Research, Jewish General Hospital, Department of Medicine, McGill University, Montreal, QC, Canada